odesivimab

{{Short description|Pharmaceutical drug}}

{{Use American English|date=October 2020}}

{{Use dmy dates|date=October 2020}}

{{Infobox drug

| drug_name =

| INN =

| type = mab

| image =

| width =

| alt =

| caption =

| mab_type = mab

| source = u

| target = Zaire ebolavirus glycoprotein

| pronounce = oh" de siv' i mab

| tradename =

| Drugs.com =

| MedlinePlus =

| licence_EU =

| DailyMedID = Odesivimab

| licence_US =

| pregnancy_AU =

| pregnancy_AU_comment =

| pregnancy_US = N

| pregnancy_US_comment =

| pregnancy_category=

| dependency_liability =

| addiction_liability =

| routes_of_administration =

| class = Monoclonal antibody

| ATCvet =

| ATC_prefix = None

| ATC_suffix =

| ATC_supplemental =

| legal_AU =

| legal_AU_comment =

| legal_BR =

| legal_BR_comment =

| legal_CA =

| legal_CA_comment =

| legal_DE =

| legal_DE_comment =

| legal_NZ =

| legal_NZ_comment =

| legal_UK =

| legal_UK_comment =

| legal_US =

| legal_US_comment =

| legal_EU =

| legal_EU_comment =

| legal_UN =

| legal_UN_comment =

| legal_status =

| bioavailability =

| protein_bound =

| metabolism =

| metabolites =

| onset =

| elimination_half-life =

| duration_of_action =

| excretion =

| CAS_number_Ref =

| CAS_number = 2135632-30-1

| CAS_supplemental =

| PubChem =

| IUPHAR_ligand =

| DrugBank_Ref =

| DrugBank =

| ChemSpiderID_Ref =

| ChemSpiderID =

| UNII_Ref =

| UNII = UY9LQ8P6HW

| KEGG_Ref =

| KEGG = D11921

| ChEBI_Ref =

| ChEBI =

| ChEMBL_Ref =

| ChEMBL =

| NIAID_ChemDB =

| PDB_ligand =

| synonyms =

| IUPAC_name =

| C = 6506 | H = 10024 | N = 1720 | O = 2030 | S = 42

| SMILES =

| StdInChI =

| StdInChI_comment =

| StdInChIKey =

| solubility =

| sol_units =

| specific_rotation =

}}

Odesivimab is a Zaire ebolavirus glycoprotein-directed human monoclonal antibody that is part of the fixed-dose combination atoltivimab/maftivimab/odesivimab that is used for the treatment of Zaire ebolavirus (Ebola virus).{{cite press release | title=FDA Approves First Treatment for Ebola Virus | website=U.S. Food and Drug Administration (FDA) | date=14 October 2020 | url=https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-ebola-virus | archive-url=https://web.archive.org/web/20201015021206/https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-ebola-virus | url-status=dead | archive-date=15 October 2020 | access-date=14 October 2020}} {{PD-notice}}{{cite press release | title=Regeneron's Antibody Cocktail REGN-EB3 (Inmazeb) is First FDA-Approved Treatment for Ebola (Zaire Ebolavirus) | website=Regeneron Pharmaceuticals Inc. | date=14 October 2020 | url=https://newsroom.regeneron.com/news-releases/news-release-details/regenerons-antibody-cocktail-regn-eb3-inmazebr-first-fda | access-date=14 October 2020}}